Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 433 articles:
HTML format
Text format



Single Articles


    November 2017
  1. LAU HH, Ng NHJ, Loo LSW, Jasmen J, et al
    The molecular functions of hepatocyte nuclear factors in and beyond the liver.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32451.
    PubMed     Text format     Abstract available


  2. LEE YH, Kim KJ, Yoo ME, Kim G, et al
    Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32448.
    PubMed     Text format     Abstract available


  3. NOBILI V, Mosca A, Scorletti E, Byrne CD, et al
    Reply 'Energy drinks and risk of non alcoholic steatohepatitis'.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32446.
    PubMed     Text format    


  4. ROBIN S, Buchanan R, Poole R
    Energy drinks and adolescents - a hepatic health hazard?
    J Hepatol. 2017 Nov 22. pii: S0168-8278(17)32444.
    PubMed     Text format    


  5. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    PubMed     Text format     Abstract available


  6. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    PubMed     Text format     Abstract available


  7. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available


  8. TERZI E, Iavarone M, Pompili M, Veronese L, et al
    Contrast enhanced ultrasound identifies hepatocellular carcinoma in cirrhosis: a large multicenter retrospective study.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32428.
    PubMed     Text format     Abstract available


  9. HU C, Li W, Tian F, Jiang K, et al
    Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
    J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32409.
    PubMed     Text format     Abstract available


  10. HAYES P, Mookerjee RP
    Early TIPS for portal hypertensive related bleeding: Is resource or education the reason for failure to show clear survival benefit?
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32410.
    PubMed     Text format    


    October 2017
  11. MOHAMMED MS, Ferrier G, Abouda G, Corless L, et al
    Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32403.
    PubMed     Text format    


  12. ASHHAB AA, Rodin H, Debes JD
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant-Authors-reply.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32404.
    PubMed     Text format    


  13. D'AMICO G, Morabito A, D'Amico M, Pasta L, et al
    Clinical states of cirrhosis and competing risks.
    J Hepatol. 2017 Oct 27. pii: S0168-8278(17)32399.
    PubMed     Text format     Abstract available


  14. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available


  15. KIM G, Jang SY, Nam CM, Kang ES, et al
    Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32397.
    PubMed     Text format     Abstract available


  16. KIM KM, Han CY, Kim JY, Cho SS, et al
    Galpha12 overexpression induced by miR16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells.
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32388.
    PubMed     Text format     Abstract available


  17. JACKSON R, Psarelli EE, Berhane S, Johnson PJ, et al
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32389.
    PubMed     Text format    


  18. BRUIX J, Cheng AL, Llovet J
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32392.
    PubMed     Text format    


  19. NAULT JC, Sutter O, Nahon P, Ganne-Carrie N, et al
    Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations.
    J Hepatol. 2017 Oct 12. pii: S0168-8278(17)32351.
    PubMed     Text format     Abstract available


  20. YU Y, Wang J, Li G, Shen C, et al
    Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32346.
    PubMed     Text format    


  21. FUJIWARA N, Friedman SL, Goossens N, Hoshida Y, et al
    Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32328.
    PubMed     Text format     Abstract available


  22. LIM C, Bhangui P, Salloum C, Gavara CG, et al
    Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32331.
    PubMed     Text format     Abstract available


    September 2017
  23. VERHOEVEN CJ, Selten JW, Roest HP, Farid WRR, et al
    Corrigendum to "MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation" [J Hepatol 2013; 59:1231-1238].
    J Hepatol. 2017 Sep 27. pii: S0168-8278(17)32279.
    PubMed     Text format    


  24. GANDHI CR
    Hepatic stellate cell activation and pro-fibrogenic signals.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32068.
    PubMed     Text format    


  25. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Reply to Letters to the Editor from Mazzarelli et al. entitled "Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything" and Tammineedi et al. entitled "More extended indication of DAA therapy in p
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32292.
    PubMed     Text format    


  26. THABUT D, Pauwels A, Carbonell N, Remy AJ, et al
    Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32281.
    PubMed     Text format     Abstract available


  27. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    PubMed     Text format    


  28. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Corrigendum to "Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma" [J Hepatol 67 (2017) 293-301].
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32207.
    PubMed     Text format    


  29. MOOKERJEE RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, et al
    Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].
    J Hepatol. 2017 Sep 8. pii: S0168-8278(17)32209.
    PubMed     Text format    


  30. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    PubMed     Text format    


  31. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    PubMed     Text format     Abstract available


  32. WANG X, Mao W, Fang C, Tian S, et al
    Dusp14 protects against hepatic ischemia-reperfusion injury via Tak1 suppression.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32275.
    PubMed     Text format     Abstract available


  33. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed     Text format    


  34. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed     Text format    


  35. URBAN SK, Krawczyk M, Willms A, Sanger H, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32262.
    PubMed     Text format    


  36. MAZZARELLI C, Cannon MD, Belli LS, Agarwal K, et al
    Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32265.
    PubMed     Text format    


  37. HUANG R, Liu Y, Wang J, Xia J, et al
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32270.
    PubMed     Text format    


  38. WANG J, Yu Y, Li G, Shen C, et al
    Relationship between serum HBV RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32261.
    PubMed     Text format     Abstract available


  39. WANG M, Shen G, Xu L, Liu X, et al
    IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-kappaB activation in hepatic macrophages.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32263.
    PubMed     Text format     Abstract available


  40. YIP TC, Chan HL, Wong VW, Wong GL, et al
    Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance".
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32266.
    PubMed     Text format    


  41. PONZIANI FR, Giarretta I, Nicoletti A, Gatto I, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32257.
    PubMed     Text format    


  42. GROSSI G, Loglio A, Facchetti F, Borghi M, et al
    Tenofovir alafenamide as a Rescue Therapy in a Cirrhotic HBV Patient with a Hystory of Fanconi Syndrome and Multidrug Resistance: A Case Report.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32260.
    PubMed     Text format     Abstract available


    August 2017
  43. SHARMA SA, Kowgier M, Hansen BE, Pieter Brouwer W, et al
    Toronto HCC Risk Index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.
    J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248.
    PubMed     Text format     Abstract available


  44. TORRECILLA S, Sia D, Harrington AN, Zhang Z, et al
    Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32252.
    PubMed     Text format     Abstract available


  45. CHIANG DY, Villanueva A
    Progress towards molecular patient stratification of hepatocellular carcinoma: lost in translation?
    J Hepatol. 2017 Aug 21. pii: S0168-8278(17)32210.
    PubMed     Text format    


  46. PETTA S, Marchesini G
    Corrigendum to "Coffee and tea breaks for liver health" [J Hepatol 67 (2017) 221-223].
    J Hepatol. 2017 Aug 16. pii: S0168-8278(17)32186.
    PubMed     Text format    


  47. REBOUISSOU S, Zucman-Rossi J, Moreau R, Qiu Z, et al
    Note of caution: contaminations of hepatocellular cell lines.
    J Hepatol. 2017 Aug 11. pii: S0168-8278(17)32206.
    PubMed     Text format    


  48. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    PubMed     Text format    


  49. MAJUMDAR A, Bailey M, Kemp WM, Bellomo R, et al
    Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32198.
    PubMed     Text format     Abstract available


  50. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    PubMed     Text format     Abstract available


  51. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    PubMed     Text format    


  52. SEBASTIAN M, Johannes M
    Is Room Temperature Susceptometry really an accurate method to assess hepatocellular iron? A response.
    J Hepatol. 2017 Aug 7. pii: S0168-8278(17)32192.
    PubMed     Text format    


  53. PAISANT A, Laine F, Gandon Y, Bardou-Jacquet E, et al
    Is Room Temperature Susceptometer really an accurate method to assess hepatocellular iron?
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32193.
    PubMed     Text format    


  54. THALHEIMER U, Giannelli V, Maimone S
    Non selective beta blockers in cirrhosis.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32194.
    PubMed     Text format    


  55. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Erratum to "Human liver regeneration in advanced cirrhosis is organized by the portal tree" [J Hepatol 66 (2017) 778-786].
    J Hepatol. 2017;67:430-436.
    PubMed     Text format    


    July 2017
  56. LEE S, Kim SH
    Reply to: "How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma".
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32156.
    PubMed     Text format    


  57. XU XF, Yu JJ, Xing H, Shen F, et al
    How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32157.
    PubMed     Text format    


  58. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    PubMed     Text format     Abstract available


  59. LEE WM
    Public Health: Acetaminophen (APAP) Hepatotoxicity- Isn't It Time for APAP to Go Away?
    J Hepatol. 2017 Jul 19. pii: S0168-8278(17)32148.
    PubMed     Text format     Abstract available


  60. NAULT JC, Paradis V, Cherqui D, Vilgrain V, et al
    Molecular classification of hepatocellular adenoma in clinical practice.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32152.
    PubMed     Text format     Abstract available


  61. PIANO S, Tonon M, Vettore E, Stanco M, et al
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32151.
    PubMed     Text format     Abstract available


  62. ZHANG S, Song X, Cao D, Xu Z, et al
    Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32149.
    PubMed     Text format     Abstract available


  63. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    PubMed     Text format    


  64. ROBERTO C, Valeria R, Cristina N, Simona B, et al
    Gut-derived endotoxin stimulates factor viii secretion from endothelial cells. implications for hypercoagulability in cirrhosis.
    J Hepatol. 2017 Jul 14. pii: S0168-8278(17)32145.
    PubMed     Text format     Abstract available


  65. FICKERT P, Wagner M
    Biliary bile acids in hepatobiliary injury - What is the link?
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)32008.
    PubMed     Text format     Abstract available


  66. GAVRIILIDIS P, Roberts KJ, Askari A, Sutcliffe RP, et al
    Evaluation of the Current Guidelines for Resection of hepatocellular carcinoma Using the Appraisal of Guidelines Research and Evaluation II Instrument.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32136.
    PubMed     Text format     Abstract available


  67. STENGEL S, Stallmach A, Richter K, Landrock A, et al
    Serum metabolic signatures in patients with overt hepatic encephalopathy.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32138.
    PubMed     Text format    


  68. WEISS N, Colsch B, Fenaille F, Junot C, et al
    Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: do we really face two different entities?
    J Hepatol. 2017 Jul 5. pii: S0168-8278(17)32140.
    PubMed     Text format    


  69. BRUIX J, Cheng AL, Meinhardt G, Nakajima K, et al
    Prognostic Factors and Predictors of Sorafenib Benefit in Patients With Hepatocellular Carcinoma: Analysis of Two Phase 3 Studies.
    J Hepatol. 2017 Jul 4. pii: S0168-8278(17)32134.
    PubMed     Text format     Abstract available


  70. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    PubMed     Text format     Abstract available


    June 2017
  71. BECK M, Schirmacher P, Singer S
    Alterations of the nuclear transport system in hepatocellular carcinoma - new basis for therapeutic strategies.
    J Hepatol. 2017 Jun 30. pii: S0168-8278(17)32122.
    PubMed     Text format     Abstract available


  72. YIP TC, Chan HL, Wong VW, Tse YK, et al
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Jun 23. pii: S0168-8278(17)32092.
    PubMed     Text format     Abstract available


  73. MARIN V, Poulsen K, Odena G, McMullen MR, et al
    Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32086.
    PubMed     Text format     Abstract available


  74. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed     Text format    


  75. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  76. ARTRU F, Louvet A, Ruiz I, Levesque E, et al
    Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32079.
    PubMed     Text format     Abstract available


  77. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    RE: Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32084.
    PubMed     Text format    


  78. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32074.
    PubMed     Text format    


  79. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed     Text format    


  80. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    PubMed     Text format    


  81. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    PubMed     Text format     Abstract available


  82. KALAMBOKIS GN, Baltayannis G, Christodoulou D, Christou L, et al
    Beta adrenergic blockade and advanced cirrhosis: does it really improve survival in patients with acute-on-chronic liver failure?
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32064.
    PubMed     Text format    


    May 2017
  83. TERATANI T, Tomita K, Suzuki T, Furuhashi H, et al
    Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity via TLR9 signaling.
    J Hepatol. 2017 May 26. pii: S0168-8278(17)32056.
    PubMed     Text format     Abstract available


  84. LU Z, Zuo B, Jing R, Gao X, et al
    Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
    J Hepatol. 2017 May 23. pii: S0168-8278(17)32055.
    PubMed     Text format     Abstract available


  85. CALDERARO J, Couchy G, Imbeaud S, Amaddeo G, et al
    Histological Subtypes of Hepatocellular Carcinoma Are Related To Gene Mutations and Molecular Tumour Classification.
    J Hepatol. 2017 May 19. pii: S0168-8278(17)32050.
    PubMed     Text format     Abstract available


  86. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Text format     Abstract available


  87. DE GALARRETA MR, Lujambio A
    Therapeutic editing of hepatocyte genome in vivo.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32048.
    PubMed     Text format     Abstract available


  88. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed     Text format    


  89. WANG Q, Lv Y, Bai M, Wang Z, et al
    Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding.
    J Hepatol. 2017 May 12. pii: S0168-8278(17)32015.
    PubMed     Text format     Abstract available


  90. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant.
    J Hepatol. 2017 May 10. pii: S0168-8278(17)32012.
    PubMed     Text format    


  91. SHIN WJ, Hwang GS
    Reply to: "Pressure volume curves in cirrhosis: more than meets the eye".
    J Hepatol. 2017 May 9. pii: S0168-8278(17)32010.
    PubMed     Text format    


  92. RIPOLL C, Yotti R, Banares R, Bermejo J, et al
    Pressure Volume Curves in Cirrhosis: more than meets the eye.
    J Hepatol. 2017 May 8. pii: S0168-8278(17)32006.
    PubMed     Text format    


  93. TAN-GARCIA A, Wai LE, Zheng D, Ceccarello E, et al
    Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32004.
    PubMed     Text format     Abstract available


  94. LEE S, Kim SH, Lee JE, Sinn DH, et al
    Preoperative Gadoxetic acid-enhanced MRI for Predicting Microvascular Invasion in Patients with Single hepatocellular carcinoma.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32005.
    PubMed     Text format     Abstract available


  95. MUELLER J, Raisi H, Rausch V, Peccerella T, et al
    Sensitive and non-invasive assessment of hepatocellular iron using a novel room-temperature susceptometer.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32000.
    PubMed     Text format     Abstract available


  96. VAUTHEY JN, Mizuno T, Overman MJ, Soubrane O, et al
    Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?
    J Hepatol. 2017 May 2. pii: S0168-8278(17)30252.
    PubMed     Text format    


  97. MOSCA A, Nobili V, De Vito R, Crudele A, et al
    Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.
    J Hepatol. 2017;66:1031-1036.
    PubMed     Text format     Abstract available


  98. SANDBOTHE M, Buurman R, Reich N, Greiwe L, et al
    The microRNA-449 family inhibits TGF-beta-mediated liver cancer cell migration by targeting SOX4.
    J Hepatol. 2017;66:1012-1021.
    PubMed     Text format     Abstract available


  99. KARLAS T, Petroff D, Sasso M, Fan JG, et al
    Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    J Hepatol. 2017;66:1022-1030.
    PubMed     Text format     Abstract available


  100. HUANG K, Du M, Tan X, Yang L, et al
    PARP1-mediated PPARalpha poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    J Hepatol. 2017;66:962-977.
    PubMed     Text format     Abstract available


    April 2017
  101. KLINGENBERG M, Matsuda A, Diederichs S, Patel T, et al
    Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30250.
    PubMed     Text format     Abstract available


  102. BRITO-AZEVEDO A
    Carvedilol and survival in cirrhosis with ascites: a cognitive bias?
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30219.
    PubMed     Text format    


  103. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  104. SEIDEL RA, Claudel T, Schleser FA, Ojha NK, et al
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30208.
    PubMed     Text format     Abstract available


  105. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  106. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Text format     Abstract available


  107. TAPPER EB, Sengupta N
    Testing for elevated liver enzymes: central to clinical Hepatology but in need of more data.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30199.
    PubMed     Text format    


    March 2017
  108. KIM JY, Park KJ, Hwang JY, Kim GH, et al
    Activating Transcription Factor 3 Is a Target Molecule Linking Hepatic Steatosis to Impaired Glucose Homeostasis.
    J Hepatol. 2017 Mar 29. pii: S0168-8278(17)30187.
    PubMed     Text format     Abstract available


  109. QURINO L, Massimo R, Jan L
    Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30180.
    PubMed     Text format    


  110. BHAT M, Ghali P, Bilodeau M
    Reply to: "Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?"
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30183.
    PubMed     Text format    


  111. PREZIOSI ME, Singh S, Valore EV, Jung CL, et al
    Mice lacking liver-specific beta-catenin develop steatohepatitis and fibrosis after iron overload.
    J Hepatol. 2017 Mar 21. pii: S0168-8278(17)30146.
    PubMed     Text format     Abstract available


  112. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    PubMed     Text format     Abstract available


  113. URBAN TJ, Nicoletti P, Chalasani N, Serrano J, et al
    Minocycline Hepatotoxicity: Clinical characterization and identification of HLA-B * 35:02 as a risk factor.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30144.
    PubMed     Text format     Abstract available


  114. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30139.
    PubMed     Text format     Abstract available


  115. VILARINHO S, Erson-Omay Z, Mitchell-Richards K, Cha C, et al
    Exome Analysis of the Evolutionary Path of Hepatocellular Adenoma-Carcinoma Transition, Vascular Invasion and Brain Dissemination.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30143.
    PubMed     Text format     Abstract available


  116. PATOURAUX S, Rousseau D, Bonnafous S, Lebeaupin C, et al
    CD44 is a key player in non-alcoholic steatohepatitis.
    J Hepatol. 2017 Mar 16. pii: S0168-8278(17)30137.
    PubMed     Text format     Abstract available


  117. TAI WT, Cheng AL, Shiau CW, Huang HP, et al
    Erratum to: Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma".
    J Hepatol. 2017 Mar 13. pii: S0168-8278(17)30118.
    PubMed     Text format    


  118. BRUIX J, Reig M, Sangro B
    Assessment of treatment efficacy in hepatocellular carcinoma: response rate, delay in progression or none of them.
    J Hepatol. 2017 Mar 8. pii: S0168-8278(17)30133.
    PubMed     Text format    


  119. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30126.
    PubMed     Text format     Abstract available


  120. TACKE F
    Targeting hepatic macrophages to treat liver diseases.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30125.
    PubMed     Text format     Abstract available


  121. JULICH-HAERTEL H, Urban SK, Krawczyk M, Willms A, et al
    Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30123.
    PubMed     Text format     Abstract available


  122. DE MATTOS AZ, de Mattos AA
    The Baveno VI criteria to identify patients not requiring endoscopic surveillance for esophageal varices - should we use it?
    J Hepatol. 2017 Mar 2. pii: S0168-8278(17)30130.
    PubMed     Text format    


    February 2017
  123. SAPISOCHIN G, Barry A, Doherty M, Fischer S, et al
    Stereotactic body radiotherapy versus TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
    J Hepatol. 2017 Feb 28. pii: S0168-8278(17)30119.
    PubMed     Text format     Abstract available


  124. ORNTOFT NW, Munk OL, Frisch K, Ott P, et al
    Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by Positrion Emission Tomography (PET).
    J Hepatol. 2017 Feb 26. pii: S0168-8278(17)30120.
    PubMed     Text format     Abstract available


  125. OBA A, Shimada S, Akiyama Y, Nishikawaji T, et al
    ARID2 modulates DNA damage response in human hepatocellular carcinoma cells.
    J Hepatol. 2017 Feb 23. pii: S0168-8278(17)30003.
    PubMed     Text format     Abstract available


  126. LUUKKONEN PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, et al
    Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
    J Hepatol. 2017 Feb 21. pii: S0168-8278(17)30109.
    PubMed     Text format     Abstract available


  127. MONTAGNESE S, De Rui M, Angeli P, Amodio P, et al
    Reply to: Tools and tactics for improving diagnosis of hepatic encephalopathy.
    J Hepatol. 2017 Feb 16. pii: S0168-8278(17)30102.
    PubMed     Text format    


  128. OLESEN SS, Jackson CD, Morgan MY
    Tools and tactics for improving diagnosis of hepatic encephalopathy.
    J Hepatol. 2017 Feb 16. pii: S0168-8278(17)30103.
    PubMed     Text format    


  129. BLERIOT C, Lecuit M
    RIPK1, a key survival factor for hepatocytes.
    J Hepatol. 2017 Feb 16. pii: S0168-8278(17)30104.
    PubMed     Text format    


  130. SINHA R, Lockman KA, Mallawaarachchi N, Robertson M, et al
    Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
    J Hepatol. 2017 Feb 14. pii: S0168-8278(17)30073.
    PubMed     Text format     Abstract available


  131. BERZIGOTTI A
    Non invasive evaluation of portal hypertension using ultrasound elastography.
    J Hepatol. 2017 Feb 13. pii: S0168-8278(17)30071.
    PubMed     Text format     Abstract available


  132. DRESCHER HK, Schippers A, Clahsen T, Sahin H, et al
    beta7-Integrin and MAdCAM-1 play opposing roles during the development of non-alcoholic steatohepatitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30065.
    PubMed     Text format     Abstract available


  133. YAMASHITA S, Shindoh J, Mizuno T, Chun YS, et al
    Hepatic Atrophy Following Preoperative Chemotherapy Predicts Hepatic Insufficiency after Resection of Colorectal Liver Metastases.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30068.
    PubMed     Text format     Abstract available


  134. WU H, Yao S, Zhang S, Wang JR, et al
    Elevated expression of Erbin destabilizes ERalpha protein and promotes tumorigenesis in hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30067.
    PubMed     Text format     Abstract available


  135. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


  136. ZHOU M, Luo J, Chen M, Yang H, et al
    Mice species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30062.
    PubMed     Text format     Abstract available


  137. DASARATHY S, Merli M
    Reply to: Myokines: a promising therapeutic target for hepatic encephalopathy.
    J Hepatol. 2017 Feb 6. pii: S0168-8278(17)30058.
    PubMed     Text format    


  138. YANG C, Luo AL
    Myokines: a promising therapeutic target for hepaticencephalopathy.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30057.
    PubMed     Text format    


  139. PRENNER S, VanWagner LB, Flamm SL, Salem R, et al
    Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy with Direct-Acting Antivirals.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30053.
    PubMed     Text format     Abstract available


    January 2017
  140. MOEINI A, Sia D, Zhang Z, Camprecios G, et al
    Mixed hepatocellular-cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30014.
    PubMed     Text format     Abstract available


  141. HEIER EC, Meier A, Julich-Haertel H, Djudjaj S, et al
    Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis.
    J Hepatol. 2017 Jan 17. pii: S0168-8278(17)30012.
    PubMed     Text format     Abstract available


  142. FILLIOL A, Piquet-Pellorce C, Raguenes-Nicol C, Dion S, et al
    RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30009.
    PubMed     Text format     Abstract available


  143. BOURSIER J, de Ledinghen V, Leroy V, Anty R, et al
    A stepwise algorithm using a at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30007.
    PubMed     Text format     Abstract available


  144. GOTO K, Kato N
    Histone deacetylase inhibitor for the treatment of hepatocellular carcinoma: chemoimmunotherapeutic perspective and prospects.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30001.
    PubMed     Text format    


  145. HANLEY J, Kumar Dhar D, Mazzacuva F, Fiadeiro R, et al
    Vps33b is Crucial for Structural and Functional Hepatocyte Polarity.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30005.
    PubMed     Text format     Abstract available


  146. BITZER M, Salih HR
    Reply to "Histone deacetylase inhibitor for the treatment of hepatocellular carcinoma: chemoimmunotherapeutic perspective and prospects".
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30004.
    PubMed     Text format    


  147. TAI WT, Cheng AL, Shiau CW, Huang HP, et al
    Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma".
    J Hepatol. 2017 Jan 6. pii: S0168-8278(16)30712.
    PubMed     Text format    


  148. YE D, Yang K, Zang S, Lin Z, et al
    Corrigendum to "Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2".
    J Hepatol. 2017 Jan 5. pii: S0168-8278(16)30711.
    PubMed     Text format    


  149. EKSTEEN B, Heatherington J, Oshiomogo J, Panaccione R, et al
    Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199].
    J Hepatol. 2017;66:254.
    PubMed     Text format    


    December 2016
  150. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed     Text format    


  151. LEBOSSE F, Testoni B, Fresquet J, Facchetti F, et al
    Intrahepatic innate immune response pathways are down-regulated in untreated chronic hepatitis B.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30757.
    PubMed     Text format     Abstract available


  152. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed     Text format    


  153. WEISS E, Rautou PE, Fasseu M, Giabicani M, et al
    Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30741.
    PubMed     Text format     Abstract available


  154. SOLTYS KA, Setoyama K, Tafaleng EN, Soto Gutierrez A, et al
    Host conditioning and rejection monitoring in hepatocyte transplantation in humans.
    J Hepatol. 2016 Dec 24. pii: S0168-8278(16)30750.
    PubMed     Text format     Abstract available


  155. WU H, Zhang T, Pan F, Steer CJ, et al
    MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
    J Hepatol. 2016 Dec 23. pii: S0168-8278(16)30749.
    PubMed     Text format     Abstract available


  156. SPRINZL MF, Galle PR
    Current progress in immunotherapy of hepatocellular carcinoma.
    J Hepatol. 2016 Dec 20. pii: S0168-8278(16)30742.
    PubMed     Text format    


  157. SCHWABL P, Hambruch E, Seeland BA, Hayden H, et al
    The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    J Hepatol. 2016 Dec 16. pii: S0168-8278(16)30710.
    PubMed     Text format     Abstract available


  158. ARROYO V, Moreau R
    Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis.
    J Hepatol. 2016 Dec 15. pii: S0168-8278(16)30577.
    PubMed     Text format    


  159. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  160. KOLLY P, Dufour JF
    Patients with hepatocellular carcinoma: Your address matters!
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30703.
    PubMed     Text format    


  161. NI Y, Urban S
    Stem cell-derived hepatocytes: a promising novel tool to study Hepatitis B Virus infection.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30704.
    PubMed     Text format    


  162. SCHWINGE D, von Haxthausen F, Quaas A, Carambia A, et al
    Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related with IL-12 signaling.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30705.
    PubMed     Text format     Abstract available


  163. MONTAGNESE S, De Rui M, Angeli P, Amodio P, et al
    Neuropsychiatric Performance in Patients with Cirrhosis: Who is "Normal"?
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30698.
    PubMed     Text format     Abstract available


    November 2016
  164. LE GUEN V, Judor JP, Boeffard F, Gauttier V, et al
    Alloantigen gene transfer to hepatocytes promotes tolerance to pancreatic islet graft by inducing CD8+ regulatory T cells.
    J Hepatol. 2016 Nov 30. pii: S0168-8278(16)30696.
    PubMed     Text format     Abstract available


  165. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Human liver regeneration in advanced cirrhosis is organized by the portal tree.
    J Hepatol. 2016 Nov 29. pii: S0168-8278(16)30690.
    PubMed     Text format     Abstract available


  166. KYRANA E, Dhawan A
    Minimal hepatic encephalopathy in children, uncommon or unrecognised? -Time to act.
    J Hepatol. 2016 Nov 28. pii: S0168-8278(16)30694.
    PubMed     Text format    


  167. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  168. PINATO DJ, Yen C, Sharma R
    Reply to comments by Chan et. al on "The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma".
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30684.
    PubMed     Text format    


  169. W H CHAN A, H W Leung H, C N Chong C, Chan SL, et al
    Comments on "The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma".
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30681.
    PubMed     Text format    


  170. CENI E, Mello T, Polvani S, Vasseur-Cognet M, et al
    The orphan nuclear receptor COUP-TFII coordinates hypoxia-independent proangiogenic responses in hepatic stellate cells.
    J Hepatol. 2016 Nov 17. pii: S0168-8278(16)30650.
    PubMed     Text format     Abstract available


  171. REIBERGER T, Mandorfer M
    Beta adrenergic blockade and decompensated cirrhosis.
    J Hepatol. 2016 Nov 15. pii: S0168-8278(16)30647.
    PubMed     Text format     Abstract available


  172. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


  173. JANJUA NZ, Chong M, Kuo M, Woods R, et al
    Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    J Hepatol. 2016 Nov 3. pii: S0168-8278(16)30637.
    PubMed     Text format     Abstract available


  174. DUFFY AG, Ulahannan SV, Makorova-Rusher O, Rahma O, et al
    Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30638.
    PubMed     Text format     Abstract available


  175. SRIVASTAVA A, Chaturvedi S, Gupta RK, Malik R, et al
    Minimal hepatic encephalopathy in children with chronic liver disease: prevalence, pathogenesis and magnetic resonance-based diagnosis.
    J Hepatol. 2016 Nov 1. pii: S0168-8278(16)30620.
    PubMed     Text format     Abstract available


    October 2016
  176. MUKHOPADHYAY P, Horvath B, Rajesh M, Varga ZV, et al
    PARP inhibition protects against alcoholic and nonalcoholic steatohepatitis.
    J Hepatol. 2016 Oct 28. pii: S0168-8278(16)30617.
    PubMed     Text format     Abstract available


  177. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed     Text format    


  178. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  179. GOUTTE N, Sogni P, Bendersky N, Barbare JC, et al
    Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country.
    J Hepatol. 2016 Oct 20. pii: S0168-8278(16)30580.
    PubMed     Text format     Abstract available


  180. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed     Text format    


  181. BHAT M, Ghali P, Dupont B, Hilzenrat R, et al
    Proposal of a Novel MELD Exception Point System for Hepatocellular Carcinoma based on Tumor Characteristics and Dynamics.
    J Hepatol. 2016 Oct 14. pii: S0168-8278(16)30571.
    PubMed     Text format     Abstract available


  182. XIA Y, Carpentier A, Cheng X, Block PD, et al
    Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions.
    J Hepatol. 2016 Oct 13. pii: S0168-8278(16)30572.
    PubMed     Text format     Abstract available


  183. FURUTA M, Ueno M, Fujimoto A, Hayami S, et al
    Whole genome sequencing discriminate hepatocellular carcinoma with intrahepatic metastasis from multicentric tumors.
    J Hepatol. 2016 Oct 11. pii: S0168-8278(16)30561.
    PubMed     Text format     Abstract available


  184. RICKE J, Seidensticker M
    Molecular imaging and liver function assessment by hepatobiliary MRI.
    J Hepatol. 2016 Oct 8. pii: S0168-8278(16)30566.
    PubMed     Text format    


    September 2016
  185. CHAYANUPATKUL M, Omino R, Mittal S, Kramer JR, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2016 Sep 28. pii: S0168-8278(16)30540.
    PubMed     Text format     Abstract available


  186. SHIN WJ, Song JG, Jun IG, Moon YJ, et al
    Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations.
    J Hepatol. 2016 Sep 26. pii: S0168-8278(16)30536.
    PubMed     Text format     Abstract available


  187. PINATO DJ, Sharma R, Allara E, Yen C, et al
    The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.
    J Hepatol. 2016 Sep 24. pii: S0168-8278(16)30535.
    PubMed     Text format     Abstract available


  188. FELIPO V, Montagnese S
    A rare and revealing glimpse of the cerebrospinal fluid of patients with hepatic encephalopathy.
    J Hepatol. 2016 Sep 24. pii: S0168-8278(16)30538.
    PubMed     Text format    


  189. VITALE A, Peck-Radosavljevic M, Giannini EG, Vibert E, et al
    Personalized Treatment of Patients with very Early Hepatocellular Carcinoma.
    J Hepatol. 2016 Sep 24. pii: S0168-8278(16)30539.
    PubMed     Text format     Abstract available


  190. VENKATESH SK, Loomba R
    Editorial: Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging.
    J Hepatol. 2016 Sep 20. pii: S0168-8278(16)30509.
    PubMed     Text format    


  191. DUCHE M, Ducot B, Ackermann O, Guerin F, et al
    Portal hypertension in children: High-risk varices, primary prophylaxis and consequences of bleeding.
    J Hepatol. 2016 Sep 20. pii: S0168-8278(16)30507.
    PubMed     Text format     Abstract available


  192. AHN SJ, Lee JM, Lee DH, Lee SM, et al
    Real-time US-CT/MR Fusion Imaging for Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30504.
    PubMed     Text format     Abstract available


  193. KOO BK, Kim D, Joo SK, Kim JH, et al
    Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    J Hepatol. 2016 Sep 3. pii: S0168-8278(16)30484.
    PubMed     Text format     Abstract available


    August 2016
  194. ROMBOUTS K, Bemeur C, Rose CF
    Targeting the muscle for the treatment and prevention of hepatic encephalopathy.
    J Hepatol. 2016 Aug 30. pii: S0168-8278(16)30474.
    PubMed     Text format    


  195. WAZIRY R, Grebely J, Amin J, Alavi M, et al
    Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).
    J Hepatol. 2016 Aug 25. pii: S0168-8278(16)30442.
    PubMed     Text format     Abstract available


  196. FERNANDEZ J, Bert F, Nicolas-Chanoine MH
    The Challenges of Multidrug Resistance in Hepatology.
    J Hepatol. 2016 Aug 17. pii: S0168-8278(16)30431.
    PubMed     Text format     Abstract available


  197. BRITO-AZEVEDO A, Perez RM, Moraes Coelho HS, Fernandes ES, et al
    The Anti-inflammatory Role of Propranolol in Cirrhosis: Preventing the Inflammatory Exhaustion?
    J Hepatol. 2016 Aug 16. pii: S0168-8278(16)30432.
    PubMed     Text format    


  198. HEDEGAARD DL, Tully DC, Rowe IA, Reynolds GM, et al
    High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease.
    J Hepatol. 2016 Aug 13. pii: S0168-8278(16)30424.
    PubMed     Text format     Abstract available


  199. MINAMI T, Tateishi R, Nakagomi R, Fujiwara N, et al
    The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.
    J Hepatol. 2016 Aug 11. pii: S0168-8278(16)30419.
    PubMed     Text format    


  200. KLOMPENHOUWER AJ, Sprengers D, Willemssen FE, Gaspersz MP, et al
    Evidence of good prognosis of hepatocellular adenoma in post-menopausal women.
    J Hepatol. 2016 Aug 11. pii: S0168-8278(16)30423.
    PubMed     Text format     Abstract available


  201. WEISS N, Hilaire PB, Colsch B, Isnard F, et al
    Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30422.
    PubMed     Text format     Abstract available


  202. LI G, Liu D, Cooper TK, Kimchi ET, et al
    Successful Chemoimmunotherapy against Hepatocellular Cancer in a Novel Murine Mode.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30420.
    PubMed     Text format     Abstract available


  203. LUUKKONEN PK, Zhou Y, Hyotylainen T, Leivonen M, et al
    The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30421.
    PubMed     Text format    


    July 2016
  204. KOLLY P, Dufour JF
    Reply to <<Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts)>>.
    J Hepatol. 2016 Jul 29. pii: S0168-8278(16)30402.
    PubMed     Text format    


  205. CARDOSO H, Vale AM, Rodrigues S, Goncalves R, et al
    High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30397.
    PubMed     Text format    


  206. MITTAL S, Kanwal F, Ying J, Chung R, et al
    Effectiveness of Surveillance for Hepatocellular Carcinoma in Clinical Practice: A United States cohort.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30395.
    PubMed     Text format     Abstract available


  207. ZENG QL, Li ZQ, Liang HX, Xu GH, et al
    Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30399.
    PubMed     Text format    


  208. PALANIYAPPAN N, Cox E, Bradley C, Scott R, et al
    Non-invasive assessment of Portal Hypertension Using Quantitative Magnetic Resonance Imaging.
    J Hepatol. 2016 Jul 27. pii: S0168-8278(16)30348.
    PubMed     Text format     Abstract available


  209. WANG HL, Cucchetti A, Zhong JH, Ye XP, et al
    Should hepatic resection be recommended to patients with hepatocellular carcinoma and portal vein invasion?
    J Hepatol. 2016 Jul 27. pii: S0168-8278(16)30349.
    PubMed     Text format    


  210. MARUBASHI S, Sakon M
    "Local recurrence" is not equal to "Local dissemination" after resection for hepatocellular carcinoma.
    J Hepatol. 2016 Jul 21. pii: S0168-8278(16)30340.
    PubMed     Text format    


  211. SHINDOH J, Hasegawa K, Matsuyama Y, Makuuchi M, et al
    Reply to: "Local recurrence" is not equal to "Local dissemination" after resection for hepatocellular carcinoma.
    J Hepatol. 2016 Jul 20. pii: S0168-8278(16)30341.
    PubMed     Text format    


  212. BENECHET AP, Iannacone M
    Determinants of hepatic effector CD8+ T cell dynamics.
    J Hepatol. 2016 Jul 13. pii: S0168-8278(16)30335.
    PubMed     Text format     Abstract available


  213. SOLA E, Kerbert JC, Verspaget HW, Moreira R, et al
    Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis.
    J Hepatol. 2016 Jul 12. pii: S0168-8278(16)30326.
    PubMed     Text format     Abstract available


  214. NAULT JC, Colombo M
    Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.
    J Hepatol. 2016 Jul 11. pii: S0168-8278(16)30327.
    PubMed     Text format    


  215. GEHRKE N, Worns MA, Huber Y, Hess M, et al
    Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.
    J Hepatol. 2016 Jul 9. pii: S0168-8278(16)30322.
    PubMed     Text format     Abstract available


  216. ALAVI M, Law MG, Grebely J, Amin J, et al
    Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012.
    J Hepatol. 2016 Jul 8. pii: S0168-8278(16)30321.
    PubMed     Text format     Abstract available


  217. YANG JD, Aqel BA, Pungpapong S, Gores GJ, et al
    Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30318.
    PubMed     Text format    


  218. STEIN E, Cruz-Lemini M, Altamirano J, Ndugga N, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30307.
    PubMed     Text format     Abstract available


  219. CHEUNG MC, Walker AJ, Hudson BE, Verma S, et al
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30314.
    PubMed     Text format     Abstract available


  220. SCHUELLER F, Roy S, Trautwein C, Luedde T, et al
    miR-122 expression is not regulated during activation of hepatic stellate cells.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30308.
    PubMed     Text format    


  221. MAURICE J, Brodkin E, Arnold F, Navaratnam A, et al
    Validation of the Baveno Vi Criteria to Identify Low Risk Cirrhotic Patients not Requiring Endoscopic Surveillance for Varices.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30316.
    PubMed     Text format     Abstract available


  222. LI J, Li S
    Response to Letter to the Editor on comments on "miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. Li J, et al. J Hepatol 2013;58:522-528."
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30315.
    PubMed     Text format    


    June 2016
  223. CHOI SH, Byun JH
    Reply to: "Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet".
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30306.
    PubMed     Text format    


  224. CONTI F, Buonfiglioli F, Scuteri A, Crespi C, et al
    Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals.
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30303.
    PubMed     Text format     Abstract available


  225. PINATO DJ, Stebbing J, Ishizuka M, Khan SA, et al
    Corrigendum to "A novel and validated prognostic index in hepatocellular carcinoma: The Inflammation Based Index (IBI)".
    J Hepatol. 2016 Jun 16. pii: S0168-8278(16)30205.
    PubMed     Text format    


  226. VAN MEER S, Lieveld FI, van Erpecum KJ
    Patients' misconceptions about surveillance for hepatocellular carcinoma: Education is needed.
    J Hepatol. 2016 Jun 16. pii: S0168-8278(16)30274.
    PubMed     Text format    


  227. KOZBIAL K, Moser S, Schwarzer R, Laferl H, et al
    Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30271.
    PubMed     Text format    


  228. DAVULURI G, Krokowski D, Guan BJ, Kumar A, et al
    Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of L-leucine in cirrhosis.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30266.
    PubMed     Text format     Abstract available


  229. RATZIU V, Marchesini G
    When the journey from obesity to cirrhosis takes an early start.
    J Hepatol. 2016 Jun 14. pii: S0168-8278(16)30207.
    PubMed     Text format    


  230. DULAI PS, Sirlin CB, SLoomba R
    MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30267.
    PubMed     Text format     Abstract available


  231. SINCLAIR M, Grossmann M, Hoermann R, Angus PW, et al
    Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30269.
    PubMed     Text format     Abstract available


  232. FORNER A, Rimola J, Ayuso C
    Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30265.
    PubMed     Text format    


  233. KALAMBOKIS GN, Oikonomou A, Christou L, Kolaitis NI, et al
    von Willebrand factor and procoagulant imbalance independently predict outcome in patients with cirrhosis and thrombocytopenia.
    J Hepatol. 2016 Jun 10. pii: S0168-8278(16)30262.
    PubMed     Text format     Abstract available


  234. POL S
    Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts).
    J Hepatol. 2016 Jun 7. pii: S0168-8278(16)30259.
    PubMed     Text format     Abstract available


  235. KOKUDO T, Hasegawa K, Matsuyama Y, Takayama T, et al
    Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.
    J Hepatol. 2016 Jun 4. pii: S0168-8278(16)30258.
    PubMed     Text format     Abstract available


  236. YE D, Yang K, Zang S, Lin Z, et al
    Lipocalin-2 Mediates Nonalcoholic Steatohepatitis by Promoting Neutrophil-Macrophage Crosstalk via The Induction of CXCR2.
    J Hepatol. 2016 Jun 4. pii: S0168-8278(16)30255.
    PubMed     Text format     Abstract available


  237. DHANASEKARAN R, Venkatesh SK, Torbenson MS, Roberts LR, et al
    Erratum to "Clinical implications of basic research in hepatocellular carcinoma" [J Hepatol 2016;64:736-745].
    J Hepatol. 2016;64:1462.
    PubMed     Text format    


  238. YEUNG OW, Lo CM, Ling CC, Qi X, et al
    Corrigendum to "Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma" [J Hepatol 2015;62:607-616].
    J Hepatol. 2016;64:1461.
    PubMed     Text format    


  239. FUNG J, Seto WK, Lai CL, Yuen J, et al
    Corrigendum to "Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy" [J Hepatol 2011;54:195-200].
    J Hepatol. 2016;64:1460.
    PubMed     Text format    


  240. SCHULZE K, Nault JC, Villanueva A
    Genetic profiling of hepatocellular carcinoma using next-generation sequencing.
    J Hepatol. 2016 Jun 1. pii: S0168-8278(16)30249.
    PubMed     Text format     Abstract available


    May 2016
  241. TORRES HA, Vauthey JN, Economides MP, Mahale P, et al
    Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment.
    J Hepatol. 2016 May 30. pii: S0168-8278(16)30248.
    PubMed     Text format    


  242. BOZIC M, Guzman C, Benet M, Sanchez-Campos S, et al
    VDR expression is up-regulated in NAFLD hepatocytes and is required for high fat diet-induced steatosis in apoE mice liver.
    J Hepatol. 2016 May 28. pii: S0168-8278(16)30243.
    PubMed     Text format     Abstract available


  243. MANDORFER M, Kozbial K, Schwabl P, Freissmuth C, et al
    Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30238.
    PubMed     Text format     Abstract available


  244. NADIM MK, Durand F, Kellum JA, Levitsky J, et al
    Corrigendum to "Management of the critically ill patients with cirrhosis: A multidisciplinary perspective".
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30185.
    PubMed     Text format    


  245. MANI SK, Zhang H, Diab A, Pascuzzi PE, et al
    EpCAM-Regulated Intramembrane Proteolysis Induces a Cancer Stem Cell-like Gene Signature in Hepatitis B Virus-infected Hepatocytes.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30208.
    PubMed     Text format     Abstract available


  246. FRANCOZ C, Nadim MK, Durand F
    Kidney Biomarkers in Cirrhosis.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30211.
    PubMed     Text format     Abstract available


  247. BOYD A, Lacombe K, Lavocat F, Maylin S, et al
    Decay of ccc-DNA is slow and marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30200.
    PubMed     Text format     Abstract available


  248. TSENG A, Wong DK
    Hepatotoxicity and Potential Drug Interaction with Ledipasvir/Sofosbuvir In HIV/HCV Infected Patients.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30201.
    PubMed     Text format     Abstract available


  249. SHEN J, Jiang F, Yang Y, Huang G, et al
    14-3-3eta, a novel growth-promoting factor in hepatocellular carcinoma, not only in tumor but also in intratumoral vessels.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30203.
    PubMed     Text format     Abstract available


  250. GIANNELLI G, Koudelkova P, Dituri F, Mikulits W, et al
    Role of epithelial to mesenchymal transition in hepatocellular carcinoma.
    J Hepatol. 2016 May 17. pii: S0168-8278(16)30193.
    PubMed     Text format     Abstract available


  251. OLESEN SS, Gram M, Jackson CD, Halliday E, et al
    Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy.
    J Hepatol. 2016 May 13. pii: S0168-8278(16)30189.
    PubMed     Text format     Abstract available


  252. ASGHARPOUR A, Cazanave SC, Pacana T, Seneshaw M, et al
    A preclinical mouse model of nonalcoholic steatohepatitis and hepatocellular cancer that mimics human disease.
    J Hepatol. 2016 May 13. pii: S0168-8278(16)30190.
    PubMed     Text format     Abstract available


  253. VANDENBULCKE H, Moreno C, Colle I, Knebel JF, et al
    Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
    J Hepatol. 2016 May 12. pii: S0168-8278(16)30184.
    PubMed     Text format     Abstract available


  254. JIAO J, Ooka K, Fey H, Fiel MI, et al
    Interleukin-15 Receptor alpha on Hepatic Stellate Cells Controls Fibrogenesis In Murine Liver Injury.
    J Hepatol. 2016 May 3. pii: S0168-8278(16)30164.
    PubMed     Text format     Abstract available


  255. BILLERBECK E, Mommersteeg MC, Shlomai A, Xiao JW, et al
    Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.
    J Hepatol. 2016 May 2. pii: S0168-8278(16)30166.
    PubMed     Text format     Abstract available


  256. TOUBAL A, Lehuen A
    Lights on MAIT cells, a new immune player in liver diseases.
    J Hepatol. 2016;64:1008-10.
    PubMed     Text format    


  257. GALLE PR
    EASL Recognition Award Recipient 2016: Prof. Jordi Bruix.
    J Hepatol. 2016;64:998-1000.
    PubMed     Text format    


  258. BOSCH J
    EASL International Recognition Award Recipient 2016: Prof. Roberto J. Groszmann.
    J Hepatol. 2016;64:996-7.
    PubMed     Text format    


  259. IJSSENNAGGER N, Janssen AW, Milona A, Ramos Pittol JM, et al
    Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    J Hepatol. 2016;64:1158-66.
    PubMed     Text format     Abstract available


  260. NOLL J, Helk E, Fehling H, Bernin H, et al
    IL-23 prevents IL-13-dependent tissue repair associated with Ly6C(lo) monocytes in Entamoeba histolytica-induced liver damage.
    J Hepatol. 2016;64:1147-57.
    PubMed     Text format     Abstract available


  261. LENCIONI R, Llovet JM, Han G, Tak WY, et al
    Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    J Hepatol. 2016;64:1090-8.
    PubMed     Text format     Abstract available


  262. LUUKKONEN PK, Zhou Y, Sadevirta S, Leivonen M, et al
    Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:1167-75.
    PubMed     Text format     Abstract available


  263. QU C, He D, Lu X, Dong L, et al
    Salt-inducible Kinase (SIK1) regulates HCC progression and WNT/beta-catenin activation.
    J Hepatol. 2016;64:1076-89.
    PubMed     Text format     Abstract available


  264. SORG UR, Behnke K, Degrandi D, Reich M, et al
    Cooperative role of lymphotoxin beta receptor and tumor necrosis factor receptor p55 in murine liver regeneration.
    J Hepatol. 2016;64:1108-17.
    PubMed     Text format     Abstract available


  265. TRIVEDI PJ, Adams DH
    Gut-liver immunity.
    J Hepatol. 2016;64:1187-9.
    PubMed     Text format     Abstract available


    April 2016
  266. OGLE LF, Orr JG, Willoughby CE, Hutton C, et al
    Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for Hepatocellular Carcinoma?
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30146.
    PubMed     Text format     Abstract available


  267. FOSTER G
    Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30142.
    PubMed     Text format    


  268. GRAY E, O'Leary A, Stewart S, Bergin C, et al
    High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30143.
    PubMed     Text format    


  269. ZHU AX, Chen D, He W, Kanai M, et al
    Integrative Biomarker Analyses Indicate Etiological Variations in Hepatocellular Carcinoma.
    J Hepatol. 2016 Apr 26. pii: S0168-8278(16)30147.
    PubMed     Text format     Abstract available


  270. ABOU-ALFA GK, Puig O, Daniele B, Kudo M, et al
    Randomized Phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.
    J Hepatol. 2016 Apr 13. pii: S0168-8278(16)30106.
    PubMed     Text format     Abstract available


  271. REIG M, Marino Z, Perello C, Inarrairaegui M, et al
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution.
    J Hepatol. 2016 Apr 12. pii: S0168-8278(16)30113.
    PubMed     Text format     Abstract available


  272. LULI S, Di Paolo D, Perri P, Brignole C, et al
    A new fluorescence based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo.
    J Hepatol. 2016 Apr 8. pii: S0168-8278(16)30104.
    PubMed     Text format     Abstract available


  273. YANG T, Shen F, Schwartz M
    Reply to: Association of blood transfusion during resection for hepatocellular carcinoma with postoperative recurrence and overall survival: a cautionary comment.
    J Hepatol. 2016 Apr 7. pii: S0168-8278(16)30102.
    PubMed     Text format    


  274. MO HY, Zhong JH, Qin HG
    Association of blood transfusion during resection for hepatocellular carcinoma with postoperative recurrence and overall survival: a cautionary comment.
    J Hepatol. 2016 Apr 4. pii: S0168-8278(16)30095.
    PubMed     Text format    


  275. VERSLYPE C
    Interfering with epigenetics in hepatocellular carcinoma: out of the shelter?
    J Hepatol. 2016 Apr 4. pii: S0168-8278(16)30098.
    PubMed     Text format    


  276. LEVRERO M, Zucman-Rossi J
    Mechanisms of HBV-induced hepatocellular carcinoma.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  277. LI W, Urban S
    Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available



  278. Corrigendum to ''Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease" [J Hepatol 2015;63:1405-1412].
    J Hepatol. 2016;64:989.
    PubMed     Text format    


  279. MUSSO G, Cassader M, Paschetta E, Gambino R, et al
    TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD.
    J Hepatol. 2016;64:979-81.
    PubMed     Text format    


  280. MARI M, Tutusaus A, Garcia de Frutos P, Morales A, et al
    Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis.
    J Hepatol. 2016;64:983-4.
    PubMed     Text format    


  281. PETTA S, Marra F
    Reply to 'Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis'.
    J Hepatol. 2016;64:984-5.
    PubMed     Text format    


  282. PIROLA CJ, Sookoian S
    The modulation of liver methylome in liver diseases.
    J Hepatol. 2016;64:987-8.
    PubMed     Text format    


  283. WIESER V, Tymoszuk P, Adolph TE, Grander C, et al
    Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease.
    J Hepatol. 2016;64:872-80.
    PubMed     Text format     Abstract available


  284. YIN H, Bogorad RL, Barnes C, Walsh S, et al
    RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver.
    J Hepatol. 2016;64:899-907.
    PubMed     Text format     Abstract available


  285. WESTBROOK RH, Dusheiko G, Williamson C
    Pregnancy and liver disease.
    J Hepatol. 2016;64:933-45.
    PubMed     Text format     Abstract available


  286. JURIC V, Ruffell B, Evason KJ, Hu J, et al
    Monocytes promote liver carcinogenesis in an oncogene-specific manner.
    J Hepatol. 2016;64:881-90.
    PubMed     Text format     Abstract available


  287. GHALLAB A, Celliere G, Henkel SG, Driesch D, et al
    Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases.
    J Hepatol. 2016;64:860-71.
    PubMed     Text format     Abstract available


  288. JUNKER AE, Gluud LL, van Hall G, Holst JJ, et al
    Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:908-15.
    PubMed     Text format     Abstract available


  289. SHERON N
    Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths.
    J Hepatol. 2016;64:957-67.
    PubMed     Text format     Abstract available


    March 2016
  290. TADA T, Kumada T, Toyoda H, Kiriyama S, et al
    HBcrAg is a predictor of hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics.
    J Hepatol. 2016 Mar 28. pii: S0168-8278(16)30086.
    PubMed     Text format     Abstract available


  291. ZHONG JH, Mo HY, Li LQ
    Hepatic venous pressure gradient for preoperative assessment of patients with resectable hepatocellular carcinoma: a comment for moving forward.
    J Hepatol. 2016 Mar 28. pii: S0168-8278(16)30082.
    PubMed     Text format    


  292. CUCCHETTI A, Cescon M, Pinna AD
    Reply to "Hepatic venous pressure gradient for preoperative assessment of patients with resectable hepatocellular carcinoma: a comment for moving forward".
    J Hepatol. 2016 Mar 26. pii: S0168-8278(16)30087.
    PubMed     Text format    


  293. GAO L, Wang PX, Zhang Y, Yu CJ, et al
    Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)30077.
    PubMed     Text format     Abstract available


  294. BRUNO S, Di Marco V, Iavarone M, Roffi L, et al
    Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075.
    PubMed     Text format     Abstract available


  295. XIE L, Wang PX, Zhang P, Zhang XJ, et al
    DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.
    J Hepatol. 2016 Mar 22. pii: S0168-8278(16)30079.
    PubMed     Text format     Abstract available


  296. ARIZA X, Graupera I, Coll M, Sola E, et al
    Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.
    J Hepatol. 2016 Mar 14. pii: S0168-8278(16)30029.
    PubMed     Text format     Abstract available


  297. LIU X, Burhans MS, Flowers MT, Ntambi JM, et al
    Hepatic oleate regulates liver stress response partially through PGC-1alpha during high-carbohydrate feeding.
    J Hepatol. 2016 Mar 11. pii: S0168-8278(16)30028.
    PubMed     Text format     Abstract available


  298. BITZER M, Horger M, Giannini EG, Ganten TM, et al
    Resminostat in combination with sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER Study.
    J Hepatol. 2016 Mar 4. pii: S0168-8278(16)30009.
    PubMed     Text format     Abstract available


  299. CURRY MP
    DAA for decompensated cirrhosis. Efficacy and safety are now established.
    J Hepatol. 2016 Mar 3. pii: S0168-8278(16)30007.
    PubMed     Text format    


  300. KIM YH, Hwang JH, Noh JR, Lee CH, et al
    Reply to "Repurposing of metformin in liver injury: The JNK conundrum".
    J Hepatol. 2016;64:750-2.
    PubMed     Text format    


  301. RAMAKRISHNA G, Sen B, Trehanpati N, Sarin SK, et al
    Repurposing of metformin in liver injury: The JNK conundrum.
    J Hepatol. 2016;64:749-50.
    PubMed     Text format    


  302. PETTA S, Valenti L, Marra F, Grimaudo S, et al
    MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:682-90.
    PubMed     Text format     Abstract available


  303. MOOKERJEE RP, Pavesi M, Thomsen KL, Mehta G, et al
    Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
    J Hepatol. 2016;64:574-82.
    PubMed     Text format     Abstract available


    February 2016
  304. TOUBOUL T, Chen S, To CC, Mora-Castilla S, et al
    Stage-specific regulation of the WNT/beta-catenin pathway results in improved differentiation of hESCs to functional hepatocytes.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00162.
    PubMed     Text format     Abstract available


  305. HANNOUN Z, Steichen C, Dianat N, Weber A, et al
    The Potential of Induced Pluripotent Stem Cell derived Hepatocytes.
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00158.
    PubMed     Text format     Abstract available


  306. BUCSICS T, Schwabl P, Mandorfer M, Peck-Radosavljevic M, et al
    Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP).
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00155.
    PubMed     Text format    


  307. ALEXOPOULOU A, Vasilieva L, Agiasotelli D, Dourakis SP, et al
    Reply to "Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis".
    J Hepatol. 2016 Feb 20. pii: S0168-8278(16)00121.
    PubMed     Text format    


  308. ADHOUTE X, Penaranda G, Raoul JL, Bourliere M, et al
    Hepatocellular carcinoma scoring and staging systems. Do we need new tools?
    J Hepatol. 2016 Feb 18. pii: S0168-8278(16)00150.
    PubMed     Text format    


  309. LIU PH, Huo TI
    Prognosis of Hepatocellular Carcinoma: Can Scores Guide Treatment Decisions?
    J Hepatol. 2016 Feb 18. pii: S0168-8278(16)00149.
    PubMed     Text format    


  310. LOUVET A
    Restoration of bactericidal activity of neutrophils by myeloperoxidase release: a new perspective for preventing infection in alcoholic cirrhosis.
    J Hepatol. 2016 Feb 13. pii: S0168-8278(16)00125.
    PubMed     Text format    


  311. VAN DER WOERD WL, Wichers CG, Vestergaard AL, Andersen JP, et al
    Defective plasma membrane targeting of p.I661T-ATP8B1, associated with familial intrahepatic cholestasis, can be rescued in vitro by CFTR correctors.
    J Hepatol. 2016 Feb 12. pii: S0168-8278(16)00076.
    PubMed     Text format     Abstract available


  312. CHIU YT, Wong JK, Choi SW, Sze KM, et al
    Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00084.
    PubMed     Text format     Abstract available


  313. BALA S, Csak T, Saha B, Zatsiorsky J, et al
    The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00078.
    PubMed     Text format     Abstract available


  314. XIANG M, Wang PX, Wang AB, Zhang XJ, et al
    Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.
    J Hepatol. 2016 Feb 6. pii: S0168-8278(16)00077.
    PubMed     Text format     Abstract available


  315. YOVCHEV MI, Locker J, Oertel M
    Biliary fibrosis drives liver repopulation and phenotype transition of transplanted hepatocytes.
    J Hepatol. 2016 Feb 5. pii: S0168-8278(16)00079.
    PubMed     Text format     Abstract available


  316. PIETRANGELO A
    Mechanisms of iron hepatotoxicity.
    J Hepatol. 2016 Feb 5. pii: S0168-8278(16)00080.
    PubMed     Text format    


  317. LEE YH, Cha BS
    Reply to "The association between sarcopenia and non-alcoholic fatty liver disease: Potential pitfalls in non-invasive prediction models".
    J Hepatol. 2016;64:520-1.
    PubMed     Text format    


  318. KIM CW, Kim HY
    The association between sarcopenia and non-alcoholic fatty liver disease: Potential pitfalls in non-invasive prediction models.
    J Hepatol. 2016;64:519-20.
    PubMed     Text format    


  319. GASTALDELLI A, Marchesini G
    Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
    J Hepatol. 2016;64:262-4.
    PubMed     Text format    


  320. ROY-CHOWDHURY J, Schilsky ML
    Gene therapy of Wilson disease: A "golden" opportunity using rAAV on the 50th anniversary of the discovery of the virus.
    J Hepatol. 2016;64:265-7.
    PubMed     Text format    


  321. LUNA JM, Michailidis E, Rice CM
    Mopping up miRNA: An integrated HBV transcript disrupts liver homeostasis by sequestering miR-122.
    J Hepatol. 2016;64:257-9.
    PubMed     Text format    


  322. MURILLO O, Luqui DM, Gazquez C, Martinez-Espartosa D, et al
    Long-term metabolic correction of Wilson's disease in a murine model by gene therapy.
    J Hepatol. 2016;64:419-26.
    PubMed     Text format     Abstract available


  323. ZUBIETE-FRANCO I, Garcia-Rodriguez JL, Martinez-Una M, Martinez-Lopez N, et al
    Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis.
    J Hepatol. 2016;64:409-18.
    PubMed     Text format     Abstract available


  324. ARMSTRONG MJ, Hull D, Guo K, Barton D, et al
    Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
    J Hepatol. 2016;64:399-408.
    PubMed     Text format     Abstract available


    January 2016
  325. FOSTER GR, Irving WL, Cheung MC, Walker AJ, et al
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jan 29. pii: S0168-8278(16)00065.
    PubMed     Text format     Abstract available


  326. TREBICKA J, von Heydebrand M, Lehmann J, Tofteng F, et al
    Assessment of beta-blocker response by expression of beta-Arrestin2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients.
    J Hepatol. 2016 Jan 28. pii: S0168-8278(16)00057.
    PubMed     Text format     Abstract available


  327. CHOI SH, Byun JH, Lim YS, Yu E, et al
    Diagnostic criteria for hepatocellular carcinoma 3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging.
    J Hepatol. 2016 Jan 25. pii: S0168-8278(16)00052.
    PubMed     Text format     Abstract available


  328. WILD SH, Morling JR, McAllister DA, Kerssens J, et al
    Type 2 diabetes, chronic liver disease and hepatocellular cancer: a national retrospective cohort study using linked routine data.
    J Hepatol. 2016 Jan 23. pii: S0168-8278(16)00020.
    PubMed     Text format     Abstract available


  329. NOIRET L, Rose CF
    Mathematical models and hepatology; oil and vinegar?
    J Hepatol. 2016 Jan 23. pii: S0168-8278(16)00055.
    PubMed     Text format    


  330. UDOMPAP P, Mannalithara A, Heo N, Kim D, et al
    Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection.
    J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014.
    PubMed     Text format     Abstract available


  331. BOSCH J, Sauerbruch T
    Esophageal varices: Stage-dependent treatment algorithm.
    J Hepatol. 2016 Jan 19. pii: S0168-8278(15)00801.
    PubMed     Text format    


  332. LUA I, Li Y, Zagory JA, Wang KS, et al
    Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers.
    J Hepatol. 2016 Jan 19. pii: S0168-8278(16)00015.
    PubMed     Text format     Abstract available


  333. YANG YH, Chen WC, Tsai YH, Chen PC, et al
    Reply to "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection".
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00011.
    PubMed     Text format    


  334. MCPHAIL MJ, Shawcross DL, Lewis MR, Coltart I, et al
    Multivariate metabotyping of plasma accurately predicts survival in patients with decompensated cirrhosis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00006.
    PubMed     Text format     Abstract available


  335. FIORE M, Leone S
    Use of anti-fungals in critically ill cirrhotic patients with spontaneous peritonitis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00013.
    PubMed     Text format    


  336. HOOFNAGLE JH
    Hepatic Decompensation during Direct-Acting Antiviral Therapy of Chronic Hepatitis C.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00010.
    PubMed     Text format    


  337. YU ML
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00012.
    PubMed     Text format    


  338. NAGAMOTO Y, Takayama K, Ohashi K, Okamoto R, et al
    Enhancement of survival rate by human iPSC-derived hepatocyte sheet transplantation in acute liver failure mice.
    J Hepatol. 2016 Jan 14. pii: S0168-8278(16)00007.
    PubMed     Text format     Abstract available


  339. JALAN R
    Journal of Hepatology, 2016.
    J Hepatol. 2016;64:5-7.
    PubMed     Text format    


  340. PAROLA M
    Age-dependent changes in extracellular matrix turnover: An under evaluated issue in the approach to chronic liver diseases.
    J Hepatol. 2016;64:13-5.
    PubMed     Text format    


  341. KARVELLAS CJ, Stravitz RT
    High volume plasma exchange in acute liver failure: Dampening the inflammatory cascade?
    J Hepatol. 2016;64:10-2.
    PubMed     Text format    


  342. CASTERA L
    Non-invasive tests for liver fibrosis progression and regression.
    J Hepatol. 2016;64:232-3.
    PubMed     Text format    



  343. EASL Clinical Practice Guidelines: Vascular diseases of the liver.
    J Hepatol. 2016;64:179-202.
    PubMed     Text format    


  344. ILYAS G, Zhao E, Liu K, Lin Y, et al
    Macrophage autophagy limits acute toxic liver injury in mice through down regulation of interleukin-1beta.
    J Hepatol. 2016;64:118-27.
    PubMed     Text format     Abstract available


  345. LARSEN FS, Schmidt LE, Bernsmeier C, Rasmussen A, et al
    High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial.
    J Hepatol. 2016;64:69-78.
    PubMed     Text format     Abstract available


  346. DYSON JK, Hutchinson J, Harrison L, Rotimi O, et al
    Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.
    J Hepatol. 2016;64:234-8.
    PubMed     Text format     Abstract available


  347. KARSDAL MA, Genovese F, Madsen EA, Manon-Jensen T, et al
    Collagen and tissue turnover as a function of age: Implications for fibrosis.
    J Hepatol. 2016;64:103-9.
    PubMed     Text format     Abstract available


  348. JIANG M, Klein M, Zanger UM, Mohammad MK, et al
    Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease.
    J Hepatol. 2016;64:44-52.
    PubMed     Text format     Abstract available


    December 2015
  349. JEFFERY HC, van Wilgenburg B, Kurioka A, Parekh K, et al
    Bacteria Exposed Biliary Epithelium and Liver B Cells Activate Intrahepatic Mait Cells in an MR1-Dependent Manner.
    J Hepatol. 2015 Dec 29. pii: S0168-8278(15)00858.
    PubMed     Text format     Abstract available


  350. OKAFOR PN, Chiejina M, de Pretis N, Talwalkar JA, et al
    Secondary Analysis of Large Databases for Hepatology Research.
    J Hepatol. 2015 Dec 28. pii: S0168-8278(15)00860.
    PubMed     Text format     Abstract available


  351. GARCIA-TSAO G
    Beta-Blockers in Cirrhosis: The Window Re-Opens.
    J Hepatol. 2015 Dec 24. pii: S0168-8278(15)00814.
    PubMed     Text format    


  352. WU L, Bartlett A, Plank L, McCall J, et al
    Validation of the Hong Kong Liver Cancer Staging System in Hepatocellular Carcinoma Patients Treated with Curative Intent.
    J Hepatol. 2015 Dec 23. pii: S0168-8278(15)00810.
    PubMed     Text format    


  353. UBEDA M, Lario M, Munoz L, Borrero MJ, et al
    Obeticholic acid reduces bacterial translocation, restores intestinal barrier and inhibits inflammation in cirrhotic rats.
    J Hepatol. 2015 Dec 23. pii: S0168-8278(15)00812.
    PubMed     Text format     Abstract available


  354. VAN MEER S, de Man RA, van Erpecum KJ
    How to implement available data on hepatocellular carcinoma surveillance in clinical practice?
    J Hepatol. 2015 Dec 22. pii: S0168-8278(15)00811.
    PubMed     Text format    


  355. FARRELL C, Cross TJ
    Re: van Meer S, de Man RA, Coenrad MJ, Sprengers D, van Nieuwkerk KMJ, Klupmpen HJ, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort study in the Netherlands. J Hepatol 2015; 63: 1156-
    J Hepatol. 2015 Dec 21. pii: S0168-8278(15)00809.
    PubMed     Text format    


  356. BOUSSIF A, Rolas L, Weiss E, Bouriche H, et al
    Impaired AKT/MAP-Kinase signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis.
    J Hepatol. 2015 Dec 21. pii: S0168-8278(15)00806.
    PubMed     Text format     Abstract available


  357. CERINI F, Vilaseca M, Lafoz E, Garcia-Irigoyen O, et al
    Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    J Hepatol. 2015 Dec 11. pii: S0168-8278(15)00804.
    PubMed     Text format     Abstract available


  358. SHERMAN M
    Staging for Hepatocellular Carcinoma: An Embarrassment of Riches.
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00803.
    PubMed     Text format    


  359. PAPATHEODORIDIS G, Dalekos G, Sypsa V, Yurdaydin C, et al
    Page-B: Risk Score for Hepatocellular Carcinoma in Caucasians with Chronic Hepatitis B Under 5-Year Entecavir or Tenofovir Therapy.
    J Hepatol. 2015 Dec 8. pii: S0168-8278(15)00795.
    PubMed     Text format     Abstract available


  360. JALAN R, De Chiara F, Balasubramaniyan V, Andreola F, et al
    Ammonia produces pathological changes in human hepatic stellate cells and is a target of therapy of portal hypertension.
    J Hepatol. 2015 Dec 1. pii: S0168-8278(15)00777.
    PubMed     Text format     Abstract available


    November 2015
  361. KOOT BG, Alders M, Verheij J, Beuers UH, et al
    A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00785.
    PubMed     Text format     Abstract available


  362. WELKER MW, Luhne S, Lange CM, Vermehren J, et al
    Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00792.
    PubMed     Text format     Abstract available


  363. MATTU S, Fornari F, Quagliata L, Perra A, et al
    The metabolic gene HAO2 is down regulated in mouse, rat and human hepatocellular carcinoma and correlates with metastasis and poor survival.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00787.
    PubMed     Text format     Abstract available


  364. HONG G, Suh KS, Suh S, Yoo T, et al
    Preoperative Alpha-fetoprotein and F-FDG PET Predict Tumor Recurrence better than Milan Criteria in Living Donor Liver Transplantation.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00791.
    PubMed     Text format     Abstract available


  365. GRONBAEK H, Rodgaard-Hansen S, Aagaard NK, Arroyo V, et al
    The soluble macrophage activation markers sCD163 and Mannose Receptor (sMR) predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    J Hepatol. 2015 Nov 27. pii: S0168-8278(15)00779.
    PubMed     Text format     Abstract available


  366. WAN X, Xu C, Lin Y, Lu C, et al
    Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism.
    J Hepatol. 2015 Nov 27. pii: S0168-8278(15)00780.
    PubMed     Text format     Abstract available


  367. VILGRAIN V, Van Beers BE, Pastor CM
    Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00774.
    PubMed     Text format     Abstract available


  368. PAGE A, Paoli P, Moran Salvador E, White S, et al
    Hepatic Stellate Cell Transdifferentiation Involves Genome-Wide Remodeling of the DNA Methylation Landscape.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00782.
    PubMed     Text format     Abstract available


  369. VERMA VK, Li H, Wang R, Hirsova P, et al
    Alcohol stimulates macrophage activation through caspase dependent hepatocyte derived release of CD40L containing extracellular vesicles.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00778.
    PubMed     Text format     Abstract available


  370. RAY KIM W, Berg T, Asselah T, Flisiak R, et al
    Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770.
    PubMed     Text format     Abstract available


  371. HELSEN N, Debing Y, Paeshuyse J, Dallmeier K, et al
    Stem cell-derived hepatocytes: a novel model for hepatitis E virus replication.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00771.
    PubMed     Text format     Abstract available


  372. GOVAERE O, Wouters J, Petz M, Vandewynckel YP, et al
    Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche.
    J Hepatol. 2015 Nov 17. pii: S0168-8278(15)00744.
    PubMed     Text format     Abstract available



  373. EASL Clinical Practice Guidelines: Liver transplantation.
    J Hepatol. 2015 Nov 17. pii: S0168-8278(15)00677.
    PubMed     Text format    


  374. NEVZOROVA YA, Cubero FJ, Hu W, Hao F, et al
    Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease.
    J Hepatol. 2015 Nov 11. pii: S0168-8278(15)00735.
    PubMed     Text format     Abstract available


    October 2015
  375. YANG T, Lu JH, Lau WY, Zhang TY, et al
    Perioperative Blood Transfusion Does Not Influence Recurrence-free and Overall Survivals after Curative Resection for Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    J Hepatol. 2015 Oct 24. pii: S0168-8278(15)00711.
    PubMed     Text format     Abstract available


  376. XU JF, Liu XY
    PIVKA-II is an independent prognostic factor for overall survival of HCC patients and maybe associated with epithelial-mesenchymal transition.
    J Hepatol. 2015;63:1040-1.
    PubMed     Text format    


    September 2015
  377. GALBOIS A, Maury E, Guidet B, Ait-Oufella H, et al
    Reply to: "Is skin mottling a predictor of high mortality in non-selected patients with cirrhosis admitted to intensive care unit?".
    J Hepatol. 2015;63:772-3.
    PubMed     Text format    


  378. CASSINOTTO C, de Ledinghen V
    Reply to: "New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?".
    J Hepatol. 2015;63:767.
    PubMed     Text format    


  379. LANTHIER N, Starkel P, Horsmans Y
    New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?
    J Hepatol. 2015;63:765-6.
    PubMed     Text format    


    August 2015
  380. KAN QC, Cui XW, Chang JM, Dietrich CF, et al
    Strain ultrasound elastography for liver diseases.
    J Hepatol. 2015;63:534.
    PubMed     Text format    


  381. VAN BEERS BE
    Reply to: "Strain ultrasound elastography for liver diseases".
    J Hepatol. 2015;63:535.
    PubMed     Text format    


    June 2015
  382. ADHOUTE X, Penaranda G, Raoul JL, Bourliere M, et al
    Reply to: ''Repeated transarterial chemoembolization: An overfitting effort?''.
    J Hepatol. 2015;62:1442-3.
    PubMed     Text format    


  383. FACCIORUSSO A, Bhoori S, Sposito C, Mazzaferro V, et al
    Repeated transarterial chemoembolization: An overfitting effort?
    J Hepatol. 2015;62:1440-2.
    PubMed     Text format    


  384. YU WL, Sun Y
    Interferon regulatory factor 9 plays a dual function in health and disease.
    J Hepatol. 2015;62:1446.
    PubMed     Text format    


  385. ZHANG XJ, Wang PX, Zhang P, Li H, et al
    Reply to: "Interferon regulatory factor 9 plays a dual function in health and disease".
    J Hepatol. 2015;62:1447-8.
    PubMed     Text format    


    May 2015
  386. FARRAR CT, DePeralta DK, Day H, Rietz TA, et al
    3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00335.
    PubMed     Text format     Abstract available


  387. MORIYA A, Iwasaki Y, Ohguchi S, Yamamoto K, et al
    Reply to: "protective effects of moderate alcohol consumption on fatty liver: a spurious association?".
    J Hepatol. 2015;62:1211-2.
    PubMed     Text format    


  388. BELL S, Britton A
    Protective effects of moderate alcohol consumption on fatty liver: a spurious association?
    J Hepatol. 2015;62:1209-11.
    PubMed     Text format    


  389. ULUCAN S, Katlandur H, Kaya Z
    Epicardial fat and liver disease; the contribution of cardio autonomic nervous system function.
    J Hepatol. 2015;62:1214.
    PubMed     Text format    


  390. CORRAO S, Rinollo C, Scaglione R
    Non-alcoholic fatty liver disease: severity of fibrosis and its relationships with clinical and biological variables.
    J Hepatol. 2015;62:1212-3.
    PubMed     Text format    


  391. PETTA S, Craxi A
    Epicardial fat in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:1215.
    PubMed     Text format    


  392. ADAMS LA, Ratziu V
    Non-alcoholic fatty liver - perhaps not so benign.
    J Hepatol. 2015;62:1002-4.
    PubMed     Text format    


  393. SIEGHART W, Hucke F, Peck-Radosavljevic M
    Transarterial chemoembolization: modalities, indication, and patient selection.
    J Hepatol. 2015;62:1187-95.
    PubMed     Text format     Abstract available


  394. LONDONO MC, Abraldes JG, Altamirano J, Decaens T, et al
    Clinical trial watch: reports from the AASLD Liver Meeting(R), Boston, November 2014.
    J Hepatol. 2015;62:1196-203.
    PubMed     Text format     Abstract available


  395. KARIMI K, Kessler T, Thiele K, Ramisch K, et al
    Prenatal acetaminophen induces liver toxicity in dams, reduces fetal liver stem cells, and increases airway inflammation in adult offspring.
    J Hepatol. 2015;62:1085-91.
    PubMed     Text format     Abstract available


  396. INAGAKI NF, Inagaki FF, Kokudo N, Miyajima A, et al
    Use of mouse liver mesothelial cells to prevent postoperative adhesion and promote liver regeneration after hepatectomy.
    J Hepatol. 2015;62:1141-7.
    PubMed     Text format     Abstract available


  397. RYU S, Chang Y, Choi Y, Kwon MJ, et al
    Age at menarche and non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:1164-70.
    PubMed     Text format     Abstract available


    April 2015
  398. BIRERDINC A, Younossi Z
    Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?
    J Hepatol. 2015;62:761-2.
    PubMed     Text format    


  399. VAN GOLEN RF, Reiniers MJ, Heger M, Verheij J, et al
    Solutions to the discrepancies in the extent of liver damage following ischemia/reperfusion in standard mouse models.
    J Hepatol. 2015;62:975-7.
    PubMed     Text format    


  400. ADHOUTE X, Penaranda G, Naude S, Raoul JL, et al
    Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.
    J Hepatol. 2015;62:855-62.
    PubMed     Text format     Abstract available


  401. GARCIA-MARTINEZ R, Andreola F, Mehta G, Poulton K, et al
    Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure.
    J Hepatol. 2015;62:799-806.
    PubMed     Text format     Abstract available


  402. ANJANI K, Lhomme M, Sokolovska N, Poitou C, et al
    Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity.
    J Hepatol. 2015;62:905-12.
    PubMed     Text format     Abstract available


  403. BOURSIER J, de Ledinghen V, Poynard T, Guechot J, et al
    An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.
    J Hepatol. 2015;62:807-15.
    PubMed     Text format     Abstract available


  404. PETTA S, Argano C, Colomba D, Camma C, et al
    Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease.
    J Hepatol. 2015;62:928-33.
    PubMed     Text format     Abstract available


  405. MORIYA A, Iwasaki Y, Ohguchi S, Kayashima E, et al
    Roles of alcohol consumption in fatty liver: a longitudinal study.
    J Hepatol. 2015;62:921-7.
    PubMed     Text format     Abstract available


  406. LAZO M, Rubin J, Clark JM, Coresh J, et al
    The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease.
    J Hepatol. 2015;62:841-7.
    PubMed     Text format     Abstract available


  407. RATZIU V, Goodman Z, Sanyal A
    Current efforts and trends in the treatment of NASH.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  408. KARLSEN TH, Lammert F, Thompson RJ
    Genetics of liver disease: From pathophysiology to clinical practice.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  409. BYRNE CD, Targher G
    NAFLD: a multisystem disease.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  410. FORBES SJ, Gupta S, Dhawan A
    Cell therapy for liver disease: From liver transplantation to cell factory.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  411. BRUIX J, Han KH, Gores G, Llovet JM, et al
    Liver cancer: Approaching a personalized care.
    J Hepatol. 2015;62.
    PubMed     Text format    


  412. BERNAL W, Lee WM, Wendon J, Larsen FS, et al
    Acute liver failure: A curable disease by 2024?
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


    March 2015
  413. LIU Y, Shao M, Wu Y, Yan C, et al
    Role for the endoplasmic reticulum stress sensor IRE1alpha in liver regenerative responses.
    J Hepatol. 2015;62:590-8.
    PubMed     Text format     Abstract available


  414. ZHOU Y, Llaurado G, Oresic M, Hyotylainen T, et al
    Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    J Hepatol. 2015;62:657-63.
    PubMed     Text format     Abstract available


  415. MARTINEZ-UNA M, Varela-Rey M, Mestre D, Fernandez-Ares L, et al
    S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:673-81.
    PubMed     Text format     Abstract available


  416. VAN BEERS BE, Daire JL, Garteiser P
    New imaging techniques for liver diseases.
    J Hepatol. 2015;62:690-700.
    PubMed     Text format     Abstract available


  417. MEIER RP, Mahou R, Morel P, Meyer J, et al
    Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice.
    J Hepatol. 2015;62:634-41.
    PubMed     Text format     Abstract available


  418. PAWLAK M, Lefebvre P, Staels B
    Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:720-33.
    PubMed     Text format     Abstract available


  419. SCHNEIDER-YIN X, van Tuyll van Serooskerken AM, Siegesmund M, Went P, et al
    Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.
    J Hepatol. 2015;62:734-8.
    PubMed     Text format     Abstract available


  420. ALTROCK E, Sens C, Wuerfel C, Vasel M, et al
    Inhibition of fibronectin deposition improves experimental liver fibrosis.
    J Hepatol. 2015;62:625-33.
    PubMed     Text format     Abstract available


    January 2015
  421. MUELLER M, Thorell A, Claudel T, Jha P, et al
    Ursodeoxycholic Acid Exerts Farnesoid X Receptor-antagonistic Effects on Bile Acid and Lipid Metabolism in Morbid Obesity.
    J Hepatol. 2015 Jan 21. pii: S0168-8278(15)00010.
    PubMed     Text format     Abstract available


  422. MOREAU R, Bataller R, Berg T, Zucman-Rossi J, et al
    From the editor's desk ...
    J Hepatol. 2015;62:6-7.
    PubMed     Text format    


  423. PECK-RADOSAVLJEVIC M
    50 years of EASL--from a European to a global perspective.
    J Hepatol. 2015;62:4-5.
    PubMed     Text format    


  424. MARCHESINI G, Mazzotti A
    NAFLD incidence and remission: only a matter of weight gain and weight loss?
    J Hepatol. 2015;62:15-7.
    PubMed     Text format    


  425. DYSON JK, Webb G, Hirschfield GM, Lohse A, et al
    Unmet clinical need in autoimmune liver diseases.
    J Hepatol. 2015;62:208-18.
    PubMed     Text format     Abstract available


  426. WONG VW, Wong GL, Yeung DK, Lau TK, et al
    Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy.
    J Hepatol. 2015;62:182-9.
    PubMed     Text format     Abstract available


  427. ARGO CK, Patrie JT, Lackner C, Henry TD, et al
    Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial.
    J Hepatol. 2015;62:190-7.
    PubMed     Text format     Abstract available


  428. FORNER A, Vilana R, Bianchi L, Rodriguez-Lope C, et al
    Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm.
    J Hepatol. 2015;62:150-5.
    PubMed     Text format     Abstract available


  429. CUBERO FJ, Zhao G, Nevzorova YA, Hatting M, et al
    Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury.
    J Hepatol. 2015;62:140-9.
    PubMed     Text format     Abstract available


    November 2014
  430. SARKAR M, Watt KD, Terrault N, Berenguer M, et al
    Outcomes in Liver Transplantation: Does Sex Matter?
    J Hepatol. 2014 Nov 26. pii: S0168-8278(14)00872.
    PubMed     Text format     Abstract available


    October 2014
  431. HAN S, Ha SY, Park CK, Joh JW, et al
    Microsteatosis may not interact with macrosteatosis in living donor liver transplantation.
    J Hepatol. 2014 Oct 27. pii: S0168-8278(14)00788.
    PubMed     Text format     Abstract available


  432. SECKLEHNER J, Richardson CA
    The reporting of animal welfare details in liver research: A review of studies describing bile duct ligation in mice (2011-2013).
    J Hepatol. 2014 Oct 1. pii: S0168-8278(14)00720.
    PubMed     Text format    


    August 2014
  433. JIMENEZ-CASTRO MB, Merono N, Mendes-Braz M, Gracia-Sancho J, et al
    The Effect of Brain Death in Rat Steatotic and Non-Steatotic Liver Transplantation With Previous Ischemic Preconditioning.
    J Hepatol. 2014 Aug 8. pii: S0168-8278(14)00535.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: